By admin 
A group of researchers led by Richard DiMarchi and Matthias Tschöp—two of the most decorated figures in the field of peptide chemistry and endocrinology—has created an experimental drug that bypasses GLP-1 entirely. Instead, this novel molecule activates the receptors for two other key metabolic hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon. In a peer-reviewed draft paper published this week in the journal Molecular Metabolism, the team presents evidence from rodent and monkey studies suggesting that this dual-agonist approach, when administered at high enough doses, can induce weight loss comparable to the industry’s current gold standards.
The implications of this study, funded by the biotech startup BlueWater Biosciences, are profound. If confirmed in human clinical trials, this discovery could pave the way for a new generation of "GLP-1-free" obesity treatments. More importantly, it offers a potential solution to the primary drawback of current therapies: the debilitating gastrointestinal side effects, such as chronic nausea and vomiting, that lead many patients to discontinue their treatment. By removing the GLP-1 component, which is widely believed to be the primary driver of these tolerability issues, DiMarchi and Tschöp hope to provide a smoother, more sustainable path to metabolic health.
The Architects of the Incretin Revolution
To understand the weight of this new hypothesis, one must first understand the pedigree of the scientists behind it. Richard DiMarchi, a former executive at Eli Lilly and a professor at Indiana University, and Matthias Tschöp, the CEO of Helmholtz Munich, are essentially the architects of the modern "multi-agonist" approach to obesity. Years ago, they pioneered the idea that single-hormone drugs were insufficient for treating a disease as complex as obesity. They argued that by combining multiple hormones into a single molecule—such as GLP-1 and GIP—scientists could achieve synergistic effects that far surpassed the efficacy of individual agents.
Their work laid the direct groundwork for tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound. Tirzepatide was a breakthrough because it was the first "twincretin," a molecule that targeted both GLP-1 and GIP receptors. It demonstrated that adding GIP to the mix could enhance weight loss while potentially mitigating some of the metabolic downsides of GLP-1. Now, DiMarchi and Tschöp are taking their own logic to its radical conclusion: If GIP and glucagon are powerful enough on their own, why do we need GLP-1 at all?
The Mechanics of the GIP/Glucagon Duo
The traditional view of metabolism often cast glucagon as the "enemy" of weight loss. Glucagon is a hormone produced by the pancreas that raises blood glucose levels by signaling the liver to release stored sugar. Because high blood sugar is a hallmark of diabetes, the idea of a drug that activates glucagon receptors was long considered counterintuitive. However, glucagon also has a secondary, highly desirable effect: it increases energy expenditure. It essentially "turns up the heat" on the body’s internal furnace, promoting thermogenesis and the burning of lipids.
GIP, meanwhile, has long been the "enigmatic" hormone of the metabolic world. For years, scientists debated whether GIP activation would help or hinder weight loss. DiMarchi and Tschöp’s earlier work proved that GIP could actually enhance the body’s sensitivity to satiety signals and improve lipid metabolism. In their new experimental molecule, the researchers use GIP to counterbalance the potential glycemic risks of glucagon. By activating both, they aim to harness glucagon’s fat-burning power while using GIP to maintain stable blood sugar levels and suppress appetite through central nervous system pathways.
In the data published this week, the researchers demonstrated that in non-human primates, this GIP/glucagon combination led to a dramatic reduction in body weight. Crucially, the animals did not exhibit the signs of malaise or "nausea-like" behaviors typically observed in monkeys treated with high doses of GLP-1. The researchers propose that at sufficiently high concentrations, the GIP/glucagon synergy creates a metabolic state that mimics the benefits of a "triple agonist" (like Lilly’s experimental retatrutide) without the sensory "noise" generated by the GLP-1 receptor in the gut and brainstem.
Challenging the Status Quo
The current obesity drug market is dominated by a "GLP-1-centric" paradigm. Novo Nordisk’s semaglutide (Wegovy) is a pure GLP-1 agonist, while Eli Lilly’s tirzepatide (Zepbound) is a GLP-1/GIP dual agonist. Even the next generation of drugs in the pipeline, such as Eli Lilly’s retatrutide, still rely on GLP-1 as one of their three pillars (GLP-1/GIP/Glucagon).
The proposal that GLP-1 is optional is likely to stir significant controversy among pharmaceutical executives and academic researchers alike. For years, the industry has funneled billions of dollars into optimizing GLP-1 delivery. If the hormone is indeed unnecessary for peak efficacy, it suggests that the industry may have been over-relying on a mechanism that carries a high "side-effect tax."
"The central notion has always been that GLP-1 is the engine and other hormones are the turbochargers," says one industry analyst. "DiMarchi and Tschöp are suggesting you can build a faster car with a completely different engine. It’s a fundamental challenge to the chemistry that defines the current market leaders."
The Tolerability Factor
The primary driver for this research is the "tolerability ceiling." While drugs like Zepbound can help patients lose 20% or more of their body weight, the "real-world" persistence rates are often lower than in clinical trials. Many patients find the nausea, diarrhea, and vomiting associated with GLP-1 drugs to be intolerable for long-term use. Furthermore, there is growing concern regarding "lean mass loss" and the "ozempic face" phenomenon, which are partly attributed to the rapid and sometimes aggressive way GLP-1 suppresses all desire for caloric intake.
A GIP/glucagon agonist could theoretically offer a more "metabolic" rather than "aversive" approach to weight loss. Instead of making a patient feel too ill to eat, the drug would focus on increasing the rate at which the body processes and burns energy, supplemented by a more subtle GIP-mediated satiety. This could result in a higher quality of life for patients and better long-term adherence, which is critical for treating a chronic condition like obesity.
The Road Ahead: From Monkeys to Men
Despite the excitement surrounding the draft paper, significant hurdles remain. The history of drug development is littered with "miracle molecules" that performed exceptionally well in rodents and monkeys but failed to show efficacy or safety in humans. The human metabolic system is notoriously complex, and the "dose-equivalence" between species is difficult to predict.
There is also the question of cardiovascular safety. Glucagon can increase heart rate, a side effect that must be carefully monitored in human trials. While the researchers argue that the GIP component helps mitigate cardiovascular strain, the FDA and other regulatory bodies will require extensive data before approving a drug that stimulates glucagon receptors at high doses.
BlueWater Biosciences, the company funding the research, is reportedly preparing for Phase 1 clinical trials. These initial human studies will focus primarily on safety and tolerability, but the world will be watching for early signs of weight loss efficacy. If the results even come close to matching the animal data, it could trigger a massive shift in biotech investment, as companies scramble to develop their own GLP-1-free alternatives.
A New Era of Metabolic Medicine?
As the global obesity epidemic continues to grow, the need for a diverse toolkit of treatments has never been more urgent. The work of DiMarchi and Tschöp suggests that we are only at the beginning of understanding the hormonal symphony that governs human weight. While GLP-1 was the first instrument we learned to play, it may not be the only one capable of leading the orchestra.
The provocative hypothesis presented this week serves as a reminder that in science, no "gold standard" is permanent. By questioning the necessity of GLP-1, these researchers are opening the door to a more personalized approach to metabolic health—one where the treatment can be tailored not just to how much weight a patient needs to lose, but to how well they can tolerate the journey. Whether or not GIP and glucagon can truly replace the GLP-1 titan remains to be seen, but the conversation has officially shifted. The "GLP-1 era" may eventually be viewed not as the destination, but as the crucial first chapter in a much larger story of metabolic discovery.